The estimated Net Worth of Richard G Vincent is at least $652 Tisíc dollars as of 13 April 2023. Mr. Vincent owns over 30,000 units of Oncternal Therapeutics stock worth over $651,749 and over the last 15 years he sold ONCT stock worth over $0. In addition, he makes $0 as Chief Financial Officer, Treasurer a Secretary at Oncternal Therapeutics.
Richard has made over 3 trades of the Oncternal Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of ONCT stock worth $9,000 on 13 April 2023.
The largest trade he's ever made was buying 30,000 units of Oncternal Therapeutics stock on 13 April 2023 worth over $9,000. On average, Richard trades about 1,979 units every 18 days since 2010. As of 13 April 2023 he still owns at least 156,859 units of Oncternal Therapeutics stock.
You can see the complete history of Mr. Vincent stock trades at the bottom of the page.
Richard G. Vincent CPA serves as Chief Financial Officer, Treasurer, Secretary of the Company. From 2012 to August 2019, Mr. Vincent worked as an independent Chief Financial Officer, and he served as Chief Financial Officer and Secretary of Sorrento Therapeutics from January 2011 through February 2015. From 2008 to January 2011, Mr. Vincent served as an independent Chief Financial Officer to several pharmaceutical, biotech and medical device companies, including Avalyn Pharma (co-founder), Meritage Pharma, and Elevation Pharmaceuticals. Mr. Vincent served as Chief Financial Officer for Verus Pharmaceuticals from 2004 to 2008, and Women First Healthcare from 2003 to 2005. Mr. Vincent’s areas of responsibility have spanned all areas of finance, treasury, investor and public relations, human resources, information technology, facilities and project management. From 1987 to 1995, Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies. Mr. Vincent became a Certified Public Accountant in California in 1989 and holds a B.S. degree in business with an emphasis in accounting from San Diego State University.
Richard Vincent is 57, he's been the Chief Financial Officer, Treasurer a Secretary of Oncternal Therapeutics since 2019. There are 10 older and 5 younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics, Inc. is Michael Carter, 82, who is the Independent Director.
Richard's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer a Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
Oncternal Therapeutics executives and other stock owners filed with the SEC include: